公开(公告)号：EP2911683A1

公开(公告)日：2015-09-02

申请号：EP13848625.3

申请日：2013-10-23

申请人： Ubivac Inc. ,  Providence Health & Services - Oregon

发明人： HILTON, Traci ,  AUNG, Sandra ,  VAN DE VEN, Rieneke ,  PAUSTIAN, Christopher ,  MOUDGIL, Tarsem ,  DUBAY, Christopher ,  TWITTY, Christopher ,  HU, Hong-Ming ,  FOX, Bernard A.

IPC分类号： A61K38/20 ,  A61K38/21 ,  A61K38/19 ,  A61P35/00

CPC分类号： C12Q1/6886 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/55522 ,  A61K2039/55561 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N33/5047 ,  G01N33/505 ,  G01N2500/10

摘要： A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types. In this way, an allogeneic, off-the-shelf cancer vaccine may be produced and made available to be administered in order to stimulate a targeted immune response in patients bearing different tumor types.

公开(公告)号：EP3055322A1

公开(公告)日：2016-08-17

申请号：EP14851719.6

申请日：2014-10-10

申请人： Ubivac, LLC ,  Providence Health & Services - Oregon

发明人： TWITTY, Christopher ,  LESHANE, Erik ,  FOX, Bernard ,  HU, Hong-Ming ,  YU, Guangjie

IPC分类号： C07K14/435 ,  A61K38/17 ,  A61P37/02

CPC分类号： A61K39/0011 ,  C12P21/00

摘要： A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products. The isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture, the tumor-derived cells being inhibited from degrading ubiquitinylated proteins via the proteasome while being grown in culture. In this way, highly immunogenic short-lived proteins and defective ribosomal products may be loaded onto dendritic cells for cross-presentation and priming of antigen-specific T cells restricted by either classical or non-classical MHC.